Press Releases Items Per Page 102550 Year None202020192018201720162015201420132012201120102007 09.20.17 Syndax Pharmaceuticals Announces Updated Presentation Time at the Cantor Fitzgerald Global Healthcare Conference 08.30.17 Syndax Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences 08.10.17 Syndax Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical and Business Update 08.03.17 Syndax to Announce Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 10, 2017 07.11.17 Preclinical Results Support Entinostat's Role in Targeting the Tumor Microenvironment to Enhance Immune Checkpoint Therapy 05.24.17 Syndax Prices Public Offering of Common Stock 05.23.17 Syndax Announces Proposed Public Offering of Common Stock 05.17.17 Syndax Announces Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Melanoma 05.16.17 Syndax Pharmaceuticals Announces Advancement of ENCORE 601 in Non-Small Cell Lung Cancer Patients with Disease Progression on or After PD-1 Therapies 05.15.17 Syndax Pharmaceuticals to Present at the 2017 UBS Global Healthcare Conference 05.08.17 Syndax Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Clinical and Business Update 05.01.17 Syndax to Announce First Quarter 2017 Financial Results and Host Conference Call and Webcast on May 8, 2017 Pagination First page « first Previous page ‹ previous … Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 … Next page next › Last page last »
09.20.17 Syndax Pharmaceuticals Announces Updated Presentation Time at the Cantor Fitzgerald Global Healthcare Conference
08.10.17 Syndax Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical and Business Update
08.03.17 Syndax to Announce Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 10, 2017
07.11.17 Preclinical Results Support Entinostat's Role in Targeting the Tumor Microenvironment to Enhance Immune Checkpoint Therapy
05.17.17 Syndax Announces Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Melanoma
05.16.17 Syndax Pharmaceuticals Announces Advancement of ENCORE 601 in Non-Small Cell Lung Cancer Patients with Disease Progression on or After PD-1 Therapies
05.08.17 Syndax Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Clinical and Business Update
05.01.17 Syndax to Announce First Quarter 2017 Financial Results and Host Conference Call and Webcast on May 8, 2017
